ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.126,63
0,29%
S&P 500
5.473,23
0,77%
Dow Jones
38.778,10
0,49%
Euro vs US Dollar
1,07141
-0,24%
Bitcoin
65.269,58
-1,83%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. PHAXIAM Therapeutics SA (PHXM)

  7. PHAXIAM Therapeutics SA (PHXM) News

PHXM

PHAXIAM Therapeutics (PHXM)

PHAXIAM Therapeutics SA
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:PHXM
DatumZeitQuelleÜberschriftSymbolFirma
11/03/202413h31Edgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:PHXMPHAXIAM Therapeutics SA
11/03/202407h00GlobeNewswire Inc.PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
06/03/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PHXMPHAXIAM Therapeutics SA
04/03/202422h28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
04/03/202422h27Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
04/03/202422h25Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
04/03/202422h22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
04/03/202422h14Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PHXMPHAXIAM Therapeutics SA
04/03/202422h09Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PHXMPHAXIAM Therapeutics SA
21/02/202412h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
20/02/202422h05GlobeNewswire Inc.PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketNASDAQ:PHXMPHAXIAM Therapeutics SA
19/01/202416h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
18/01/202422h05GlobeNewswire Inc.PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024NASDAQ:PHXMPHAXIAM Therapeutics SA
16/11/202313h41Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
14/11/202322h05GlobeNewswire Inc.PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023NASDAQ:PHXMPHAXIAM Therapeutics SA
25/10/202315h21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
24/10/202322h05GlobeNewswire Inc.PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusNASDAQ:PHXMPHAXIAM Therapeutics SA
23/10/202322h05GlobeNewswire Inc.TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationNASDAQ:PHXMPHAXIAM Therapeutics SA
11/10/202312h53Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
05/10/202313h32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
26/09/202321h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
21/09/202314h42Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
18/09/202314h16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
15/09/202314h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
07/09/202315h33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
27/07/202322h21Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHXMPHAXIAM Therapeutics SA
 Showing the most relevant articles for your search:NASDAQ:PHXM

Kürzlich von Ihnen besucht

TG
J19
Rural Funds
BIT
UB60N5
Unicredit Bank
BIT
F18240
Vontobel Financial Produ...
TG
A383H8
Porsche Automobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten